Preventing and Curing Rotavirus Infection
News Nov 17, 2014
Activation of the innate immune system with the bacterial protein flagellin could prevent and cure rotavirus infection, which is among the most common causes of severe diarrhea, says a Georgia State University research team that described the method as a novel means to prevent and treat viral infection.
Rotavirus is most problematic in infants and young children, who can become severely dehydrated and require hospitalization. Rotavirus causes about 500,000 deaths annually worldwide in children younger than five years of age, according to the Centers for Disease Control and Prevention.
The research, performed in mice, was led by Dr. Andrew Gewirtz and Dr. Benyue Zhang of the Institute for Biomedical Sciences at Georgia State, and included collaborators at Emory University School of Medicine, Baylor College of Medicine, Vanderbilt University School of Medicine, Genentech Inc. and the Pennsylvania State University.
Flagellin stopped rotavirus by rapidly inducing an immune response that would normally be activated by select bacteria rather than a virus. Flagellin triggered the innate immune system, which provides an immediate response to pathogens, to produce two proteins: Interleukin-22, which prevented the virus from entering cells, and Interleukin-18, which removed existing rotavirus from infected cells. Consequently, the antiviral effect of the bacterial protein was fully recapitulated by use of the interleukin proteins.
“We’ve described a completely novel way to combat a viral infection by use of a bacterial-derived activator of the immune system,” Gewirtz said. “It’s analogous to equipping an NFL defense with baseball bats. Blatant violation of all the rules but yet, at least in this case, very effective.”
Some viral infections can be prevented by vaccines, which “teach” the adaptive immune system to recognize specific viruses. Some viral infections are managed by use of select drugs that directly attack the virus. Such approaches typically require years of research and development and are generally applicable to a single target virus.
“What we’ve done is to broadly activate the innate immune system in a manner that will likely impede a wide range of viruses,” Gewirtz said.
The researchers expect the specific method used in their work, using flagellin or the IL-22 and IL-18 proteins it elicits, might be effective against a range of chronic viral infections of the digestive system such as norovirus and hepatitis C virus. The team is now planning studies in humans to test this hypothesis. The general model of activating innate immunity to combat viral infection should prove an effective means of slowing down most any virus and could be a temporary means to deal with a broad range of viral infections until more specific solutions could be developed, Gewirtz said.
The research study was primarily funded by the National Institutes of Health.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.